All News

In regard to potentially dangerous exposure to parabens, researchers aim to clarify the role of OTC liquid drugs among children.

This episode explores a specific generalization within pharmacy practice that leaders should actively avoid while simultaneously looking toward overcoming key hurdles affecting team members.

Clinical pharmacists boost A1c control and eye and foot screening for Spanish-speaking adults with diabetes, revealing why culturally fluent care matters.

Through the lens of geographic and racial accessibility, researchers explore OTC naloxone sales and costs in North Carolina.

Pharmacists’ word choices shape insulin-pump trust, reduce diabetes stigma, and uncover hidden needs—boosting adherence and A1C outcomes.

Previously, bimagrumab monotherapy in adults with type 2 diabetes led to a 20.5% reduction in total body fat mass and a 0.76 percentage point decrease in hemoglobin A1c.

Pneumococcal aortitis is a rare but life-threatening aortic infection that highlights the concerning interplay between pneumococcal disease and cardiovascular disease risk and mortality.

Harps pharmacists reveal how smart workflow powers point‑of‑care testing, prescribing, and billing—scalable clinical services for regional chains.

Lani Bertrand, senior director of clinical marketing & thought leadership at Omnicell, discusses the consistent drivers of drug shortages in the US.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

GLP-1 diabetes drugs show promise in cutting addiction risk and overdose deaths, hinting at new options for substance use disorder prevention and care.

Once weekly petrelintide, a long-acting amylin analog, delivers up to 10.7% weight loss with placebo-like gastrointestinal tolerability in phase 2.

With its initial rollout beginning in 2026, the Medicare Drug Price Negotiation Program has caused significant strain on the cash flow of independent pharmacies.

With a growing prevalence of medication use across the US, researchers explore overall use of OTC and prescription drugs from June 2023 to April 2024.

In older adults with type 2 diabetes, low body mass index signals higher mortality risk.

Precision nutrition reshapes type 2 diabetes prevention, using genes, epigenetics, and microbiome insights to tailor diets that improve glycemic control.

With a key exemption under DSCSA expiring at the end of the year, Matt Sample from Cencora helps pharmacies understand the tools and processes they need now to best comply with the law.

Weekday sleep near 7 hours optimizes insulin sensitivity, and too little or too much could harm metabolism.

Pharmacists are taking the lead to combat misinformation on measles and preserve the nation’s fragile elimination status.

Matt Sample, senior vice president of manufacturer, quality, and replenishment operations at Cencora, discusses DSCSA compliance hurdles, VRS tools, and a new push toward 12-digit NDCs.

Episode 8 explores the real-world evidence, clinical trial data, and overall application of finerenone for pharmacists and their patients.

Phase 3 data show subcutaneous risankizumab boosts remission and endoscopic healing in moderate-to-severe Crohn cases, with familiar safety and easier dosing.

FDA targets telehealth ads for compounded glucagon-like peptide-1s, warning of misleading claims, hidden sources, and safety risks amid social media hype.

FDA expands lomitapide use to children 2 years and older, highlighting major low-density lipoprotein reductions.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

The FDA expands the drug's usage to treat idiopathic short stature, small for gestational age, and growth failure associated with Noonan syndrome.

Matt Sample from Cencora discusses current DSCSA developments on the rise for pharmacy businesses in 2026—namely small dispensers that have been under exemption.